Pharmdca (@Pharmdca) header
Pharmdca (@Pharmdca) profile picture

USC Pharmacy Alumni 💊 | Full-Time Investor 📈 My posts reflect my personal investment views, not investment recommendations. Always do your own due diligence.

United States
Joined September 2013
Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)
LT position PART 1 Portfolio Positions acquired: $RNA $DAWN $SLNO $NARI $BPMC $MYOV base:0x9bba915f036158582c20b51113b925f243a1a1a1 $KRTX $HZNP $PRVB $ISEE $BLU $CTIC $FSTX $ICVX $LVGO $STML base:0x4e6c9f48f73e54ee5f3ab7e2992b2d733d0d0b07 $CMRX $RLYP $ITCI $KVUE Tech positions: In order $AMZN $META $NVDA $MSFT $SOFI $GOOGL $RDDT $MELI $APP $RKLB $INTC $IREN $NBIS $CRDO $AAOI $BE $AXON $MDB Biotech positions: $VKTX $CYTK $ARDX $HROW $MDGL $CRVS $ABVX $TMDX $RVMD $NKTR $CELC $AVR
9
8
41
63,414
$ABVX In a nutshell from my investing experience in Biotech sector. It takes years of execution, clinical success, and capital allocation to build value in a company and garner investor confidence. Yet it can take just one short report to inject uncertainty and erase months of progress in the eyes of the market. Destroying sentiment can take a single short report.
1
1,015
$SPY just shy away from $700 print. What a month it has been so far.
8
3,179
$ABVX The market valuation has been cut nearly in half from its highs. At current levels, the company could become a much more attractive acquisition target for BP.
1
1
12
3,380
$ABVX Scorpion Short report- Another one taking advantage of current market conditions.
1
1
29
6,948
$ABVX What happened- Down 20%
4
7
8,537
$RVMD clearing event. Stock down on anticipation of $ERAS data this morning. Pullback is a good opportunity to add $RVMD demonstrating a clear transitioning into commercial stage post drug launch with revenue of $198 million in just 5 weeks (partial quarter). Company is moving into transformational period with no competition for next few years and to expand into earlier clinical settings and validation across other cancers like NSCLC etc.
1
9
4,976
I rather buy $SPCX than $ANT
4
33
6,245
SANDISK $SNDK 8-FOR-1 STOCK SPLIT IS NOW EFFECTIVE
25
51
13
912
120,902
TRUMP WILL DELIVER A KEYNOTE ADDRESS ON THE IRAN WAR NEXT MONTH: THE NEW YORK POST
24
11
10
194
46,309
Pharmdca retweeted
$RVMD Lifesci PT $338 $RVMD: status quo maintained within pan-RAS space; headline figures include 60.7% ORR, 11.1 months mDOR, 12.8 months mPFS, and 76.6% landmark OS at 12 months in N=61 frontline PDAC patients with 18.3 months median follow-up (see also Prior AACR 2026 Data). We'd also flag an 8.2% rate of CR, as well as a 95% CI for mPFS ranging from 10.8-18.4 months. Competitor $ERAS reads out a larger N but nonetheless early (and somewhat uninterpretable) dataset that clears a minor overhang for $RVMD
$RVMD TRUIST BUY PT$261 Near term,expect investors to focus on tomorrow’s ERAS-0015 believe the principal debate will center on response depth, particularly in KRAS G12D PDAC. Expectations for ERAS-0015 appear to call for ~40-50% overall ORR and potentially 50%+ in G12D, in our investor discussions, which would compare favorably with Rasonque monotherapy’s 30% overall ORR and 24% ORR in G12D. That said, we believe ORR alone is unlikely to resolve the competitive debate. Rasonque has already demonstrated statistically significant OS benefit across RAS subtypes in a randomized ph.III study, including a 0.49 OS HR in G12D, while becoming increasingly entrenched in 2L+ PDAC. In our view, ERAS-0015 and other competitors would ultimately need durable survival data and likely a head-to-head study against Rasonque to fully establish clinically meaningful superiority. Bottom line: focus remains on Rasonque launch execution and its expansion into 1L PDAC
5
9
3,924
Pharmdca retweeted
$RVMD TRUIST BUY PT$261 Near term,expect investors to focus on tomorrow’s ERAS-0015 believe the principal debate will center on response depth, particularly in KRAS G12D PDAC. Expectations for ERAS-0015 appear to call for ~40-50% overall ORR and potentially 50%+ in G12D, in our investor discussions, which would compare favorably with Rasonque monotherapy’s 30% overall ORR and 24% ORR in G12D. That said, we believe ORR alone is unlikely to resolve the competitive debate. Rasonque has already demonstrated statistically significant OS benefit across RAS subtypes in a randomized ph.III study, including a 0.49 OS HR in G12D, while becoming increasingly entrenched in 2L+ PDAC. In our view, ERAS-0015 and other competitors would ultimately need durable survival data and likely a head-to-head study against Rasonque to fully establish clinically meaningful superiority. Bottom line: focus remains on Rasonque launch execution and its expansion into 1L PDAC
$RVMD - Bottomline duration going to be much better then most revenue models had. 👍 high numbers will only go higher $RVMD seems good value here with one of best launches many will see in there lifetime ?
1
4
1
15
7,930
BREAKING: Senate passes Trump-backed bill to speed up permits for power plants, power lines, and data centers in a 62-33 vote.
89
761
119
8,776
473,049
$RVMD First line Metastatic Pancreatic cancer- Bar is set for $ERAS In the updated analysis, the confirmed objective response rate was 60.7% (95% confidence interval [CI]: 47.3–72.9), including complete responses in 8.2% of patients. The disease control rate was 90.2% (95% CI: 79.8–96.3) and median duration of response was 11.1 months (95% CI: 7.6- 18.4). Median progression free survival (PFS) was 12.8 months (95% CI: 10.8–18.4) and the twelve-month overall survival was 76.6% (95% CI: 63.7-85.4).
4
2
1
27
9,383
Pharmdca retweeted
$RVMD Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026 •With additional patients and longer follow-up, the combination of RASONQUE plus gemcitabine and nab-paclitaxel demonstrated deep and durable responses in the first-line treatment setting •Results support the ongoing Phase 3 RASolute 303 trial in patients with treatment-naïve metastatic pancreatic cancer
2
7
2
34
8,345
I like his analysis here $NVDA
Body Language Analysis of Colette Kress, NVIDIA's Interim CEO:
9
14
234
70,654
$IVVD interim data imminent per management. I had closed my full position on last run up from $0.5+ to $1 Bought shares back as a lotto play with good risk reward here around $0.46 Cash in hand $0.43 so very limited downside but stock could hit 100-150% from these levels on good data.
2
14
8,132
Two stock moving catalysts $ERAS & $IVVD $ERAS ph1 Pancreatic cancer data tomorrow- Very likely a clearing event for $RVMD $RVMD stock has been down post Earnings release ON anticipation of $ERAS data which is too early in development.
4
9
8,227
$META PLANS $300 MUSE CHARM WITH FREE VERIZON 5G, TARGETS 10M WEARABLE DEVICE SALES IN H2 2026 Meta plans to price its pocket-sized Muse Charm AI device at $300, with up to 12 months of free Verizon 5G service to access its Muse AI assistant. The company has delayed its smartwatch launch to 2027 to prioritize Charm, using technology originally developed for the watch. Meta has also set an internal target of selling 10 million wearable devices in the second half of 2026 and reaching nearly 7 million monthly active wearable users by year-end. For context, EssilorLuxottica reported selling more than 7 million pairs of Ray-Ban Meta smart glasses in 2025. Sorce: The Information
36
19
14
326
59,185
Pharmdca retweeted
🚨 BREAKING: MARK ZUCKERBERG FIRES BACK AT NVIDIA OVER JENSEN HUANG'S DEPARTURE, QUESTIONS THE COMPANY'S DECISION TO LET GO OF ONE OF THE MOST IMPORTANT LEADERS IN THE TECHNOLOGY INDUSTRY! 🗣️ Mark Zuckerberg stated: "Look, I think what Jensen Huang has built at Nvidia is extraordinary. You don't simply walk away from decades of leadership, innovation and experience and expect everything to continue as if nothing happened. Jensen wasn't just running a company; he was building an ecosystem. His relationships, technical knowledge and ability to bring talented people together played a massive role in making Nvidia what it is today. I understand that companies have standards and boards have difficult decisions to make. But leadership is also about recognising the value someone brings beyond the numbers on a financial report. You can find another CEO, but finding someone who understands the business, the people and the vision at the same level is an entirely different challenge. I believe Nvidia should carefully reconsider what it stands to lose. Sometimes, the biggest mistake a company can make is failing to recognise the value of the person who helped build its success." Nvidia's decision has sparked serious debate across Silicon Valley, with prominent technology figures questioning whether the company can truly replace Huang's influence.
🚨 BREAKING: ELON MUSK SLAMS NVIDIA OVER JENSEN HUANG'S DEPARTURE, COMPARES THE DECISION TO THE CHICAGO BULLS DUMPING MICHAEL JORDAN AND SAYS THE COMPANY MAY HAVE MADE A MASSIVE MISTAKE! Elon Musk has strongly criticised Nvidia over its reported decision to force Jensen Huang out, arguing that losing a leader of his calibre could be a disastrous move for the company. 🗣️ Musk said: "I DON'T THINK HE'S DISLOYAL TO THE UNITED STATES." "Let's say you're the Chicago Bulls. You're on a winning streak, and then you kick Michael Jordan off your team. DOESN'T seem like a smart decision to me!" Musk believes Jensen is virtually irreplaceable, pointing to his exceptional leadership, deep understanding of technology, supply-chain expertise and decades-long industry relationships. He also highlighted the loyalty Jensen commands within Nvidia, saying several members of his team have rejected more lucrative offers elsewhere because they want to continue working with him. President Trump also expressed that it would be great to see Jensen return to Nvidia. Musk added that hiring Jensen would be an honour for him, although he doesn't believe the former Nvidia leader is currently looking for another job. NVIDIA MAY HAVE JUST MADE A HUGE MISTAKE!
76
431
26
3,036
209,865
$AMD SAYS HUNTERBROOK CLAIMS MISREPRESENT AMD'S PRACTICES
22
45
4
695
62,906